01.21.26 -- How Should Scientific Focus Change In 2026? Researchers Weigh In

Fast-track your early-phase cancer trial in Australia with world-class sites, expert teams, and streamlined regulatory approval.

Explore the common misconceptions surrounding reconsent, as well as the reality of its ability to be a flexible, ethics-driven communication practice grounded in respect for participant autonomy.

Project FrontRunner represents a paradigm shift in oncology drug development, championing earlier-line studies to bring novel treatments to patients sooner.

While clinical trial planning often emphasizes rapid enrollment, sustained patient retention is equally vital to success.

By incorporating flexibility, statistical rigor, and continuous learning, adaptive designs strengthen early-phase oncology programs and support faster, more confident progression into later-stage development.

Modern adaptive Phase 1 oncology trials speed timelines, refine dosing, and meet FDA standards, replacing outdated 3+3 methods to boost efficiency, safety, and regulatory success.

Health Economics and Outcomes Research (HEOR) plays a vital role in guiding evidence-based decisions across the healthcare ecosystem.

From balancing treatment ratios and managing eligibility to accommodating site-specific readiness and protocol amendments, a well-designed IRT system enables seamless transitions.

The FDA's regulatory endorsement of DCTs enhances their credibility, offering a pathway to more inclusive and accessible clinical research that benefits both patients and sponsors.

Explore how mobile phlebotomy is transforming clinical trial participation by making specimen collection more accessible, convenient, and patient-centric.